Online inquiry

IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11060MR)

This product GTTS-WQ11060MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets EGFR&LGR5 gene. The antibody can be applied in Colorectal Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001346897.2; NM_001277226.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956; 8549
UniProt ID Q504U8; O75473
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ11060MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8430MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HSP90mab
GTTS-WQ15472MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA UCB-0107
GTTS-WQ15505MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA UCB-7665
GTTS-WQ12941MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PankoMab
GTTS-WQ10141MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LBR-101
GTTS-WQ12098MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MOR-03087
GTTS-WQ11550MR IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MGA031
GTTS-WQ15474MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA UCB-0107
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW